Kyntra Bio’s Last Shot Is an Oral Anemia Drug It Can’t Afford to Test
A CD46 ADC failure forces a pure-play MDS pivot — and the Phase III still hinges on capital that doesn’t exist yet.
KYNB · Earnings Call · 2026-11-16
The pivot nobody wanted
Kyntra Bio’s third-quarter call was not a normal quarterly update; it was a forced reset. The company killed its lead oncology program after an interim efficacy miss: “Unfortunately, based upon insufficient interim efficacy results that did not meet the threshold required to support continued development, we have made the decision to terminate the phase II study of FG-3246 and FG-3180.” — Thane Wettig, Chief Executive Officer · 2026-11-16 The keyword record shows how complete the break is. In the prior quarter, Kyntra’s top themes were CD46 expression, non-PSMA approaches, Pluvicto sequencing and PET imaging. Those concepts did not disappear because the market lost interest; they disappeared because the asset did. The new top keywords are lower-risk MDS, high transfusion burden patients, MATTERHORN study and oral option — the vocabulary of roxadustat, the one program left. The contrast with the prior call is brutal. In May, management still expected FG-3246 to reach mature data:Seven months later, the program is being returned to Fortis and wound down. The tape already voted. KYNB is an $8.3M microcap whose stock is down 70.9% over the last 90 trading days and 73.3% from its July peak; the full-history drawdown is 99.9%. This is not a market-wide wave. Global curated themes this quarter are macro and AI — Fed rate hike, Grok bot, tariff and election noise — none of which explains Kyntra. This is company-unique binary risk.However, we do expect given the hurdle that we've set, we do expect the asset to continue on until we see the more fully mature rPFS data in 2027.